Cinromide plus ASMs vs placebo plus ASMs
Seizure freedom · Lennox‐Gastaut syndrome, any age
1 finding from 1 review
- no estimate extracted1 study · 56 participantsVery low
Findings
What do systematic reviews say?
4 questions · 4 findings · 1 reviews
No studies found 1 · 25%GRADE not reported 0 · 0%Very low 3 · 75%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Cinromide plus ASMs vs placebo plus ASMs
Number of participants with ≥ 75% reduction in mean weekly seizures · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 75% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- Peto OR 9.35 [0.45, 194.96]1 study · 56 participantsVery low
Cinromide plus ASMs vs placebo plus ASMs
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
It is very uncertain whether cinromide plus ASMs changes number of participants with ≥ 50% reduction in mean weekly seizures compared with placebo plus ASMs (very low certainty).
1 finding from 1 review
- RR 1.15 [0.47, 2.86]1 study · 56 participantsVery low
Cinromide plus ASMs vs placebo plus ASMs
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found